[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f5Ms5YY8bIMXxxer2QetzBKdDU9pigFJDHksexA5IfTs":8,"$fw6tKYfzNKzjLxvjTtkh1BQ50QGDXrDKgJHF9pRP9t7M":55,"$f3yMBAYVTHrwtkJY0yd70pw-aXzafjB4hrlsfAm7Bwt8":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65364,868612,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//aEjvqWJyaGzRDDYxpbM3JGk58uOu7fQX.png","李俊杰","桓台县人民医院","血管外科","主治医师",16,0,"肝癌早期介入治疗与阿帕替尼：您的实用指南","","https://ystcdn.venuertc.com/venue/AI/90cd467f-93b1-41bf-a76a-1dc658f6ddb6.jpg","\u003Cdiv id=\"material_title\" class=\"apatinib-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">肝癌早期介入治疗与阿帕替尼：您的实用指南\u003C/h1>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、阿帕替尼概览：什么样的药？🧬\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    阿帕替尼（Apatinib）是一种口服小分子抗肿瘤靶向药，属于血管生成抑制剂类。它主要通过抑制肿瘤新生血管的形成来阻断肿瘤的营养供应。阿帕替尼已被广泛用于多种实体肿瘤的治疗领域，近年来也在肝癌的治疗中得到认可，并纳入医保。这篇指南将从7个重要角度，助您把握阿帕替尼的正确使用方法、注意事项、常见问题和用药安全重点。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二、药理机制：阿帕替尼是怎么“工作”的？💡\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    阿帕替尼的作用核心在于：抑制VEGFR-2（血管内皮生长因子受体-2）的活性，阻断肿瘤细胞周围新血管的生成，进而降低肿瘤的血流和营养供应，对肿瘤的生长起到“断粮”作用。这种机制让它通常用于需要抑制异常血管生长的场合，并成为后线治疗的一种选择。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">正确理解：\u003C/span> 阿帕替尼不是“杀死”细胞，而是“饿死”肿瘤组织，因此属于典型的抗血管生成药物。\n  \u003C/p>\n\u003C/div>\n  \n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">三、剂型、规格与服用技巧 🎯\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    阿帕替尼主流剂型为薄膜衣片，常见规格为250mg片剂和500mg片剂。应整片吞服，不可咀嚼、掰开或研碎。服药时需用足量温水送服，一般建议每次至少用200ml水。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">特别提醒：\u003C/span> 肠溶片剂型若出现，请严格遵医嘱服用，勿随意拆开或改变剂型。\n  \u003C/p>\n  \u003Cp>\n    \u003Cstrong>案例一：\u003C/strong> 一位患者口服阿帕替尼后，因未用足量水送服而出现口腔黏膜不适。正确做法：每次服用须以充足温水送服，避免药物黏附口腔或食道表面。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">四、用法用量：怎么吃最合理？📅\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    \u003Cspan class=\"apatinib-highlight\">常规用法：\u003C/span> 一般建议每日一次，且在同一时段规律服用，餐前或餐后均可。部分人群可能会因耐受性或合并症调整剂量，需根据实际医生处方执行。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">正确做法：\u003C/span>\n    \u003C/p>\u003Cul class=\"apatinib-list\">\n      \u003Cli>固定时间服用，便于形成服药习惯及监测副作用。\u003C/li>\n      \u003Cli>如漏服，应在24小时内尽快补服，逾期不补，多服不利于疗效反而易加副作用。\u003C/li>\n    \u003C/ul>\n    \u003Cstrong>案例二：\u003C/strong> 有患者用药后出现漏服，尝试加倍服用，结果导致副作用加剧。正确做法：漏服请勿叠加，直接按下次正常剂量服用。\n  \u003Cp>\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">五、药物相互作用：哪些药不能同吃？🚫\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    服用阿帕替尼期间，有些药物或补品会影响其代谢或增加副作用，甚至降低疗效。例如：\n    \u003C/p>\u003Cul class=\"apatinib-list\">\n      \u003Cli>含CYP3A4酶诱导剂如利福平、苯妥英钠，可明显降低阿帕替尼血药浓度。\u003C/li>\n      \u003Cli>强CYP3A4抑制剂如伊曲康唑、红霉素，可明显升高血药浓度，增大毒副反应风险。\u003C/li>\n      \u003Cli>抗凝药（如华法林）同服，可能增加出血风险。\u003C/li>\n      \u003Cli>胃酸抑制剂如奥美拉唑可影响阿帕替尼的吸收。\u003C/li>\n    \u003C/ul>\n    \u003Cspan class=\"apatinib-highlight\">正确做法：\u003C/span> 用药期间如要合并其他药物，建议提前咨询医生或药师评估有无风险，并调整给药时间或剂量。\n  \u003Cp>\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">六、特殊人群用药指南 👪\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    \u003Cspan class=\"apatinib-highlight\">1. 老年人\u003C/span>：肝功能下降时建议减量启动，并加强副反应监测。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">2. 儿童\u003C/span>：尚无足够安全性和有效性数据，一般不推荐儿童使用。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">3. 孕妇和哺乳期妇女\u003C/span>：阿帕替尼对胎儿有潜在风险，故怀孕、哺乳期间禁用。如处特殊情况必须用药，应在医生明确指导下权衡利弊。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">4. 肝肾功能不全者\u003C/span>：轻度受损者按医生建议调整剂量，中至重度功能不全慎用或禁用，尤其需注意停药指征。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">七、常见不良反应及其应对 🌡️\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    阿帕替尼的常见不良反应包括：高血压、蛋白尿、手足综合征、口腔黏膜炎、食欲减退、轻度恶心或腹泻等。国际多中心研究显示，约10%-30%的患者可能出现高血压或蛋白尿，严重病例需临时停药处理（Qin et al., 2021）。\n  \u003C/p>\n  \u003Cul class=\"apatinib-list\">\n    \u003Cli>\n      高血压：定期监测血压，首次升高时及时报告。\n    \u003C/li>\n    \u003Cli>\n      蛋白尿：查尿常规，发现异常需减少剂量或停药，严重者立即就医。\n    \u003C/li>\n    \u003Cli>\n      手足麻木、疼痛：轻者可局部护肤，重症者需及时告知医师。\n    \u003C/li>\n    \u003Cli>\n      恶心腹泻：多为短期现象，可用止泻类药物、调节饮食缓解。\n    \u003C/li>\n  \u003C/ul>\n  \u003Cspan class=\"apatinib-highlight\">特别提醒：\u003C/span> 如出现持续性呕吐、剧烈腹泻、无法缓解的头痛头晕，或有明显出血症状，应立即停药并前往医院处理。\n  \u003Cp>\n    \u003Cstrong>案例三：\u003C/strong> 一位长期服用阿帕替尼的患者，因未能及时监测血压，后出现高血压急症被送医。正确做法：定期自测血压和相关指标，是保障长期安全用药的关键。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">八、储存与保管：别让药效“溜走” 🗂️\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    阿帕替尼需避光、密封、常温（不高于30℃）保存，远离潮湿、强光和儿童。开启后的药品建议30天内服用完毕，若发现药片颜色变化或有异味，应丢弃不用。不宜与食品或化学品混放，避免污染。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">正确做法：\u003C/span> 原瓶密封，每次取用后即刻拧紧瓶盖，药品过期或变质及时带到药店指定回收点丢弃。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">九、漏服与过量：别慌，记住这几步 ⏰\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    \u003Cspan class=\"apatinib-highlight\">1. 漏服\u003C/span>：如漏服时间在24小时内，立即补服；超过24小时则不补直接按下次正常剂量服用。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">2. 过量\u003C/span>：若误服剂量超标，可能增加副作用风险，如高血压、严重蛋白尿等。此时应立刻停止用药，并带上药品包装尽快就医。\n    \u003Cbr>\n    \u003Cspan class=\"apatinib-highlight\">正确做法：\u003C/span> 养成规律服药的好习惯，可用药盒或提醒手机，降低漏服和误服风险。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十、用药案例：《介入+靶向》联合用药小结 📝\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    实际用药过程中，阿帕替尼联合介入治疗可以实现互补优势。然而，一些细节需格外留心：\n    \u003C/p>\u003Cul class=\"apatinib-list\">\n      \u003Cli>联合化疗时须关注肝肾功能及血常规变化，按周期检测指标。\u003C/li>\n      \u003Cli>长期服药者建议建立自我监测日志，把服药情况及不适反应随时记录。\u003C/li>\n      \u003Cli>定期复查是把握用药安全与疗效的必备措施。\u003C/li>\n    \u003C/ul>\n    \u003Cstrong>用药经验：\u003C/strong> 某男患者长期按医嘱规律口服阿帕替尼并结合介入治疗，在定期检测、充分关注副作用的基础上，实现了良好耐受。此类经验提示：标准化管理与科学用药，是发挥药效、降低风险的关键。\n  \u003Cp>\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十一、如何让家人一起安全用药？👨‍👩‍👦\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    家属可协助整理服药时间表、定期协助测压、帮忙观察皮肤、黏膜等身体变化。发现异常迹象第一时间记录并报告医生。\n    \u003Cspan class=\"apatinib-highlight\">友情建议：\u003C/span> 可采用药盒、闹钟提醒、定期沟通等方式，共同营造更科学的用药氛围，这对合并多种基础用药的人群尤为重要。\n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-subtitle-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十二、全程用药复盘：三个关键习惯提升安全性🛡️\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    \u003C/p>\u003Cul class=\"apatinib-list\">\n      \u003Cli>\u003Cspan class=\"apatinib-bold\">规律服药与监测\u003C/span>：每天固定时间服药，结合自测血压、尿蛋白观察。\u003C/li>\n      \u003Cli>\u003Cspan class=\"apatinib-bold\">不随便调整剂量或停药\u003C/span>：服药前出现不适请及时和医生反馈，切勿自行增减剂量或突然停药。\u003C/li>\n      \u003Cli>\u003Cspan class=\"apatinib-bold\">警惕药物相互作用\u003C/span>：如需加用新药，一定提前和医生或药师沟通，获取专业评估。\u003C/li>\n    \u003C/ul>\n    \u003Cspan class=\"apatinib-highlight\">记住：\u003C/span> 只要管理到位，大多数人都可以顺利完成规范疗程。\n  \u003Cp>\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-conclusion-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：阿帕替尼使用的两大重点🌱\u003C/h2>\n  \u003C/div>\n  \u003Cp>\n    阿帕替尼作为靶向药物，为肝癌等多种疾病治疗带来了更多可能。最重要的是：\u003Cspan class=\"apatinib-bold\">规律服药，专人管理，预防和监测副作用\u003C/span>。如遇用药难题，及时与医生或药师沟通。安全用药，从每一个细节做起——不仅让治疗过程更顺利，也让生活更安心。\n  \u003C/p>\n  \u003Cp>\n    \u003Cstrong>建议：\u003C/strong>将本指南内容收藏，和家人朋友一起分享用药安全知识，让每一次服药都心中有数，远离风险。 \n  \u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"apatinib-section\">\n  \u003Cdiv class=\"apatinib-citation-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献（英文）\u003C/h2>\n  \u003C/div>\n  \u003Col class=\"apatinib-citation-list\">\n    \u003Cli>\n      Qin, S., Li, Q., Gu, S., Chen, X., Lin, L., Wang, Z., ... & Cheng, Y. (2021). Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. \u003Ci>Lancet Gastroenterology & Hepatology, 6\u003C/i>(7), 559-568. https://doi.org/10.1016/S2468-1253(21)00153-1\n    \u003C/li>\n    \u003Cli>\n      Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., ... & Qin, S. (2021). Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial. \u003Ci>Clinical Cancer Research, 27\u003C/i>(4), 1003-1011. https://doi.org/10.1158/1078-0432.CCR-20-3344\n    \u003C/li>\n    \u003Cli>\n      El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., ... & Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. \u003Ci>Lancet, 389\u003C/i>(10088), 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2\n    \u003C/li>\n    \u003Cli>\n      National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2024. Retrieved from https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1469\n    \u003C/li>\n  \u003C/ol>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立的全局样式，仅对本组件生效 */\n\n.apatinib-title {\n  background: linear-gradient(90deg,#f5fafc 0%,#e2f3fa 100%);\n  padding: 24px 32px;\n  text-align: center;\n  margin-bottom: 40px;\n  border-radius: 24px;\n  box-shadow: 0 4px 16px rgba(60,150,150,0.05);\n}\n\n.apatinib-section {\n  margin: 0 auto 44px auto;\n  max-width: 840px;\n  padding: 0 10px;\n}\n\n.apatinib-subtitle-bg {\n  background: linear-gradient(120deg,#eff9f0 30%,#eef4fb 100%);\n  padding: 20px 30px;\n  border-radius: 16px;\n  margin-bottom: 20px;\n  position: relative;\n  font-size: 1.25em;\n  box-shadow: 0 1px 4px rgba(136,196,216,0.05);\n}\n\n.apatinib-conclusion-bg {\n  background: linear-gradient(120deg,#fbf4ed 30%,#e7f5e6 100%);\n  padding: 20px 30px;\n  border-radius: 16px;\n  margin-bottom: 20px;\n  box-shadow: 0 1px 4px rgba(136,196,216,0.06);\n}\n\n.apatinib-citation-bg {\n  background: linear-gradient(120deg,#eef4fa 30%,#f4fcff 100%);\n  padding: 20px 30px;\n  border-radius: 16px;\n  margin-bottom: 20px;\n  box-shadow: 0 1px 4px rgba(136,196,216,0.06);\n}\n\n.apatinib-section h2 {\n  margin: 0 0 0 3px;\n  font-size: 1.3em;\n  font-weight: 700;\n  color: #268486;\n  letter-spacing: 1px;\n}\n\n.apatinib-list {\n  margin: 12px 0 12px 22px;\n  padding-left: 0;\n  color: #305365;\n}\n.apatinib-list li {\n  padding-left: 0.5em;\n  margin-bottom: 5px;\n  font-size: 1em;\n}\n\n.apatinib-highlight {\n  color: #ff884e;\n  font-weight: 600;\n}\n\n.apatinib-bold {\n  font-weight: bold;\n  color: #20303f;\n}\n\n.apatinib-citation-list {\n  padding-left: 24px;\n  color: #5f748e;\n}\n\n.apatinib-citation-list > li {\n  margin-bottom: 10px;\n  font-size: 1em;\n  line-height: 1.6em;\n}\n\n@media only screen and (max-width: 600px) {\n  .apatinib-title {\n    padding: 18px 5px;\n    font-size: 1.2em;\n  }\n  .apatinib-section {\n    padding: 0 3px;\n  }\n  .apatinib-subtitle-bg,\n  .apatinib-conclusion-bg,\n  .apatinib-citation-bg {\n    padding: 15px 7px;\n    font-size: 1em;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv id=\"material_title\" class=\"apatinib-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em ",249,"2025-09-01 15:57:38","阿帕替尼, 肝癌, 介入治疗, 抗肿瘤药物, 用药指南, 副作用, 药物相互作用, 高血压, 治疗方案","全面解析阿帕替尼的使用方法与注意事项，让您安全、有效地对抗肝癌，保障治疗效果。适合肝癌患者及家属阅读。","2025-09-08 13:25:48",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]